Delcath Systems Stock

Delcath Systems FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Delcath Systems (DCTH) as of Jul 25, 2026 is 776.63 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 72.92 % — a change of 965.08% (higher).

FCF Conversion

776.63 %

YoY

965.08%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Delcath Systems is 2026 776.63 % . FCF Conversion Rate (FCF/EBITDA) of Delcath Systems was 2025 72.92 % . It decreases by 965.08% higher compared to the previous year.
Access this data via the Eulerpool API

Delcath Systems Stock analysis

What does Delcath Systems do? Delcath Systems Inc is a US-American medical technology company specializing in the development of innovative products for the treatment of various forms of liver cancer. The company was founded in 1988 in New York and is headquartered in Queensbury today. Delcath Systems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Delcath Systems stock

FCF Conversion Rate (FCF/EBITDA) of Delcath Systems is 776.63 % in 2026.

Access this data via the Eulerpool API

Cash Flow — Delcath Systems

All Key Metrics — Delcath Systems